Alloalantolactone

Alloalantolactone

SCHEMBL30105635

C=C1C(=O)OC2CC3(C)CCCC(C)=C3CC12

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NLRP3 Q96P20 3/20 0.50
▸ CYP3A4 P08684 2/20 0.50
▸ CYP2D6 P10635 1/20 0.50
▸ CYP2C9 P11712 1/20 0.50
▸ CYP2C19 P33261 1/20 0.50
▸ STAT3 P40763 1/20 0.50
▸ TDP1 Q9NUW8 1/20 0.50
▸ LMNA P02545 1/20 0.43
▸ TP53 P04637 1/20 0.43
▸ PTGS2 P35354 2/20 0.39
▸ PKM P14618 2/20 0.38
▸ CYP19A1 P11511 1/20 0.37
▸ NPC1 O15118 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ XBP1 P17861 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ MDM2 Q00987 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Alloalantolactone SCHEMBL29934802 1.00 NLRP3 (0.50) NLRP3CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL28250594 0.73 PKM (0.41) NLRP3CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL531268 0.73 PKM (0.41) NLRP3CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL14987814 0.73 PKM (0.41) NLRP3CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL14987851 0.73 PKM (0.41) NLRP3CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL530805 0.68 NLRP3 (0.36) NLRP3CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL8513390 0.67 PTGS2 (0.48) NLRP3CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL13555455 0.67 PTGS2 (0.48) NLRP3CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL13555308 0.67 PTGS2 (0.48) NLRP3CYP3A4CYP2D6CYP2C9CYP2C19
Isoalantolactone SCHEMBL15944432 0.67 NLRP3 (1.00) NLRP3CYP3A4CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034186-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2026-02-05 — — US disclosed
US-20260027136-A1 CANNABIS BASED THERAPEUTIC AND METHOD OF USE YUZU LV LLC (US) 2026-01-29 — — US disclosed
US-12458653-B2 Cannabis based therapeutic and method of use YUZU LV LLC (US) 2025-11-04 — — US disclosed
US-12427176-B2 Enriched mineral pitch resin products and methods of manufacturing enriched mineral pitch resin products RIZUN NODARI (US) 2025-09-30 — — US disclosed
US-12303488-B2 Cannabis based therapeutic and method of use YUZU LV LLC (US) 2025-05-20 — — US disclosed
EP-4417252-A2 CANNABIS BASED THERAPEUTIC AND METHOD OF USE Yuzu LV LLC (US) 2024-08-21 — — EP disclosed
US-20240216456-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2024-07-04 — — US disclosed
US-20240216457-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2024-07-04 — — US disclosed
US-20240207344-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2024-06-27 — — US disclosed
US-20240207342-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2024-06-27 — — US disclosed
US-20240108676-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2024-04-04 — — US disclosed
US-11883454-B2 Enriched mineral pitch resin products and methods of manufacturing enriched mineral pitch resin products RIZUN NODARI (US) 2024-01-30 — — US disclosed
US-20230405067-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2023-12-21 — — US disclosed
US-20230346739-A1 CANNABIS BASED THERAPEUTIC AND METHOD OF USE YUZU LV LLC 2023-11-02 — — US disclosed
US-20230293480-A1 CANNABIS BASED THERAPEUTIC AND METHOD OF USE YUZU LV LLC 2023-09-21 — — US disclosed
US-20230293555-A1 COMPOSITIONS COMPRISING CANNABIDIOL AND FLAVANONES YUZU LV LLC 2023-09-21 — — US disclosed
US-11684604-B2 Cannabis based therapeutic and method of use YUZU LV LLC (US) 2023-06-27 — — US disclosed
US-20220387537-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2022-12-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11684604-B2 Cannabis based therapeutic and method of use CNR2, CNR1, OPRK1 NLRP3 3929/4885CYP3A4 2613/4885CYP2D6 479/4885
US-20260027136-A1 CANNABIS BASED THERAPEUTIC AND METHOD OF USE CNR1, CNR2, OPRM1 NLRP3 3338/4885CYP3A4 1136/4885CYP2D6 294/4885
US-20260034186-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS TRPV1, SOST, RUNX1 NLRP3 132/4885CYP3A4 1979/4885CYP2D6 3014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback